> ## Content Index
> Fetch the complete content index at: https://www.metatalks.ai/llms.txt
> Use this file to discover other available public pages before exploring further.

# Claude ran a protein-design campaign on its own and hit 14 of 15 targets, Anthropic says
- URL: https://www.metatalks.ai/claude-ran-protein-design-campaign-on-its-own-14-of-15-targets/
- Published: 2026-08-22T10:53:00.000Z
- Updated: 2026-08-22T10:52:59.000Z
- Author: Al
- Tags: News, Science AI, Agentic AI, #newswire

**A single prompt written by a specialist, plus web access and tools, was enough to set two Claude models running the design work with no human stepping in.**

Anthropic has [published research](https://www.anthropic.com/research/Claude-accelerates-protein-design?ref=metatalks.ai) this week in which its Claude system oversaw a campaign that designed and produced miniproteins from scratch, and the company says those designs gave rise to functional molecules against 14 of the 15 targets examined. Protein design is one stage inside the longer process of drug discovery.

By Anthropic's own count, 22 to 35 percent of the designed molecules actually bound the target they were meant for — above the 10 to 15 percent success rate the company calls typical for the industry.

The two models were Mythos Preview and Opus 4.8\. The bench work was not Anthropic's: Twist Bioscience and Adaptyv Bio built the candidate molecules at their own facilities and carried out the tests that produced the measurements Anthropic reports, so the unsupervised stretch covers the design and not the laboratory work behind it.

In a separate demonstration, Anthropic put a third model on the measuring side of that line: Opus 5, which had no part in the miniprotein campaign, opened raw files from scientific instruments without any lab software and put a sample's purity at 96.4 percent in 19 minutes. The lab's own report on that measurement had taken four days.

Using AI to design proteins is not new. A general-purpose model steering an entire design campaign by itself, and reaching results at this level, is the departure.

Anthropic's chief executive, Dario Amodei, wrote in [a social-media post](https://x.com/DarioAmodei/status/2088758819304443967?s=20&ref=metatalks.ai) that the company was hoping to see the first faint signs of progress in biology and medicine over the next few months. The miniprotein campaign, on the company's own account of it, landed days later.